3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
4
Recruiting
2
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
59
Genitourinary
13
Gynecologic
10
Thoracic
6
Other solid neoplasm
5
Head & Neck
5
Breast
5
Endocrine
3
Tumor-Agnostic
2
Sarcoma
2
Other hematologic neoplasm
1
NET
1
CNS
1
Conditions
Sarcoma
1
GIST
1
Interventions
Doxorubicin
25
Cyclophosphamide
24
pembrolizumab
20
Specimen Handling
19
Temozolomide
16
Magnetic Resonance Spectroscopy
15
Surgical Procedures, Operative
14
Radiotherapy
13
Blood Specimen Collection
13
Biopsy
13
atezolizumab
12
Gemcitabine
12
fludarabine
11
Vincristine
11
Ifosfamide
11
X-Rays
8
Trabectedin
8
Nivolumab
8
Irinotecan
8
Imatinib Mesylate
8
Drug Therapy
8
cabozantinib
7
Surveys and Questionnaires
7
Radiation
7
liposomal doxorubicin
5
abemaciclib
5
Sunitinib
5
Standard of Care
5
Radiation Dose Hypofractionation
5
Dactinomycin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
lenvatinib
×
Sarcoma
×
Clear all
NCT07096609
2026-04-03
LONGIST
Asan Medical Center
Phase 1/2
Recruiting
48 enrolled
NCT07359053
2026-01-22
MAGNATE-S
Shanghai 6th People's Hospital
Phase 2
Recruiting
46 enrolled